vTv Therapeutics Inc. (VTVT)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

23,33

-0,44

(-1,85%)

Alla chiusura: 04:00PM EDT

23,95

+0,62

(+2,66%)

Dopo ore:

04:34PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	56,759M
Beta (mensile su 5 anni)	0,52
Rapporto PE (ttm)	N/D
EPS (ttm)	-8,72
Prossima data utili	09 ago 2024 - 13 ago 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	N/D

Tutte

GlobeNewswire
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the first half of 2023, we made further progress in the development of cadisegliatin as an ad
GlobeNewswire
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that Cantex Pharmaceuticals, Inc. recently obtained an exclusive worldwide license